APLN and neoplasm: Sunitinib treatment of NeuT;Apln+/+ tumors increased the percentage of hypoxic cells adjacent to tumor blood vessels compared to untreated NeuT;Apln+/+ tumors, evaluated by prototypic carbonic anhydrase 9 (CA9) immunostaining (Fig 5A; Olive et al, 2001).